Impact of different methods of treatment of hip osteoarthritis on the clinical manifestations during short- and long-term observation
The course of coxarthrosis, its short-term and long-term prognosis remains sufficiently unknown, and the influence of one or another method of treatment on the course of the disease and the time of onset of irreversible changes is still the subject of scientific research. The aim of the study is to evaluate the dynamics of clinical data in patients with the initial stages of coxarthrosis in the observation interval of 1–5 years with various treatment regimens that include both medical therapy and arthroscopic intervention. The analysis of the dynamics of clinical parameters (using the modified Harris scale) in the course of various treatment methods (non-steroidal anti-inflammatory drugs with / without chondroprotector or hyaluronic acid) with a group of arthroscopically operated patients was carried out after 1, 3 and 5 years from the diagnosis of 225 patients with initial stages coxarthrosis. All quantitative data obtained are processed by variational statistics methods (Wilkoxon test for 2 groups of dependent populations and Mann-Whitney U-test for 2 groups of independent populations). It has been established that the combination of NSAID therapy with symptom-modifying delayed-action drugs contributes to the solution of individual therapeutic problems in patients with coxarthrosis during the short and medium term observation period. Reception of chondroprotectors improves the effectiveness of pain control, intra-articular administration of hyaluronic acid contributes to a longer preservation of the motor function of the affected joint. The most effective method in overcoming the progression of loss of motor function of the hip joint and increasing the intensity of the pain syndrome is arthroscopic treatment. The obtained data allow us to state that arthroscopy has a pathogenetic and preventive orientation, slows the progression of the disease and, as a consequence, improves the patient's quality of life.
2. Mironov, S. P., Omelyanenko, N. P. & Orleckij, A. K. (2001). Osteoartroz: Sovremennoe sostoyanie problemy (analiticheskij obzor). [Osteoarthrosis: Current state of the problem (analytical review)]. Vestnik travmatologii i ortopedii im. N.N. Priorova – Herald of traumatology and orthopedics named after N.N. Priorov, 2, 96–99.
3. Iaremenko, D. O., Shevchenko O. H. & Holubova, I. V. (2008). Stan i struktura pervynnoi invalidnosti pry zakhvoriuvanniakh suhlobiv. [Condition and structure of primary disability in joint diseases]. Litopys travmatolohii ta ortopedii – Chronicle of traumatology and orthopedics, 1–2, 133–135.
4. Bruyère, O., Altman, R. D. & Reginster, J. Y. (2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin. Arthritis Rheum., 45(4), 12–17. doi: 10.1016/j.semarthrit.2015.11.011.
5. Ethgen, O., Bruyère, O. & Richy, F. (2004). Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J. Bone Joint Surg. Am., 5(86А), 963–974. DOI: 10.2106/00004623-200405000-00012.
6. Frank, J. M., Harris, J. D., & Erickson, B. J. (2015). Prevalence of Femoroacetabular Impingement Imaging Findings in Asymptomatic Volunteers: A Systematic Review. Arthroscopy, 6(31), 1199–1204. doi: 10.1016/j.arthro.2014.11.042.
7. Harris, W. H. (1969). Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment of mold arthroplasty. J. Bone Jt. Surg., 54А, 61–76.
8. Hawker, G. A., Mian, S., & Kendzerska, T. (2011). Measures of adult pain. Arthritis Care Res. (Hoboken), 11(63), 240–252. doi: 10.1002/acr.20543.
9. Puljak, L., Marin, A., & Vrdoljak, D. (2017). Celecoxib for osteoarthritis. Cochrane Database Syst. Rev., 5: CD009865. doi: 10.1002/14651858.CD009865.pub2.
10. Roman-Blas, J. A., Castañeda, S., Sánchez-Pernaute, O., Largo, R. & Herrero-Beaumont, G. (2017). Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol., 1(69), 77–85. doi: 10.1002/art.39819.
11. Salaffi, F., Carotti, M., & Stancati, A. (2005). Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging. Clin. Exp. Res., 4(17), 255–263. DOI:10.1007/s10067-004-0965-9.
12. Singh, J. A., Noorbaloochi, S., & Mac Donald, R. (2015). Chondroitin for osteoarthritis. Cochrane Database Syst. Rev., 1:CD005614. doi: 10.1002/14651858.CD005614.pub2.
13. Vasiliadis, H. S., & Tsikopoulos, K. (2017). Glucosamine and chondroitin for the treatment of osteoarthritis. World J. Orthop., 1(8), 1–11. doi:10.5312/wjo.v8.i1.1.
14. Wesseling, J., Welsing, P. M., & Bierma-Zeinstra, S. M. (2013). Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study. Rheumatology (Oxford), 1 (52), 180–188. doi: 10.1093/rheumatology/kes288.
15. Witteveen, A. G., Hofstad, C. J., & Kerkhoffs, G. M. (2015). Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle. Cochrane Database Syst. Rev., 10:CD010643. doi: 10.1002/14651858.CD010643.pub2.
16. Zhang, W., Doherty, M., & Arden, N. (2005). EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force ofи the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis., 5(64), 669–681. DOI: 10.1136/ard.2004.028886.
This work is licensed under a Creative Commons Attribution 4.0 International License.